Search

Cliona Mary Rooney

from Bellaire, TX
Age ~68
Get Report
Also known as:
Cliona M Rooney, Cliona Mary Rooney Brenner, Cliona M Brenner, Cliona Rooney Brenner, Brenner Cliona Rooney, Cliona R Brenner, Cliona R, Cloina Rooney
Phone and address:
4802 Willow St, Bellaire, TX 77401
(713) 665-0573
Related to:
Joshua M Brenner, 30Malcolm K Brenner, 73Daniel BrennerBenjamin Brenner, 28Lara J Brenner, 33
Connected to:
Adrian J Rooney, 59Aren J Rooney, 52Arlene E Rooney, 93Benjamin Rooney, 48Bethlyn R Rooney, 77Brooke E Rooney, 37Charline J Rooney, 95Christinet A Rooney, 59Columbus Rooney, 32Cristin Rooney, 68

Cliona Rooney Phones & Addresses

  • 4802 Willow St, Bellaire, TX 77401 (713) 665-0573
  • Houston, TX
  • Memphis, TN

Work

Company: Texas children's hospital Address: 6621 Fannin St, Houston, TX 77030 Phones: (832) 824-1000 Position: Phd full member Industries: Offices and Clinics of Doctors of Medicine

Resumes

Resumes

Cliona Rooney Photo 1

Professor, Department Of Pediatrics , Section Of Hematology Oncology

View page
Location:
Houston, TX
Industry:
Research
Work:
Baylor College of Medicine
Professor
Cliona Rooney Photo 2

Professor

View page
Location:
Bellaire, TX
Work:
Baylor College of Medicine
Professor

Business Records

Name / Title
Company / Classification
Phones & Addresses
Cliona Rooney
Phd Full Member
Texas Children's Hospital
Offices and Clinics of Doctors of Medicine
6621 Fannin St, Houston, TX 77030
Cliona Rooney
Phd Full Member
Texas Children's Hospital
Offices and Clinics of Doctors of Medicine
6621 Fannin St, Houston, TX 77030

Publications

Us Patents

Bi-Spcific Chimeric T Cells

View page
US Patent:
20030148982, Aug 7, 2003
Filed:
Nov 8, 2002
Appl. No.:
10/290720
Inventors:
Malcolm Brenner - Bellaire TX, US
Claudia Rossig - Muenster, DE
Cliona Rooney - Bellaire TX, US
International Classification:
A61K048/00
A61K039/12
C12N005/08
C12N015/867
US Classification:
514/044000, 424/093210, 435/372000, 435/456000
Abstract:
The present invention is directed to a bi-specific chimeric T lymphocyte, wherein the lymphocyte comprises both an antigen-specific receptor, such as for Epstein-Barr Virus, and a chimeric receptor, such as for a tumor. In a particular embodiment, administration of an Epstein-Barr Virus T lymphocyte with an 14.G2a- antitumor chimeric receptor is utilized for therapy of neuroblastoma.

Methods Of Cell Culture For Adoptive Cell Therapy

View page
US Patent:
20110136228, Jun 9, 2011
Filed:
Dec 8, 2010
Appl. No.:
12/963597
Inventors:
Juan F. Vera - Bellaire TX, US
Cliona M. Rooney - Bellaire TX, US
Ann M. Leen - Bellaire TX, US
John R. Wilson - New Brighton MN, US
International Classification:
C12N 5/00
US Classification:
435373
Abstract:
An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cmif the growth surface is not comprised of gas permeable material and up to 2 ml/cmif the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×10cells/cmat the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×10cells/cm.

Generation Of Ctl Lines With Specificity Against Multiple Tumor Antigens Or Multiple Viruses

View page
US Patent:
20110182870, Jul 28, 2011
Filed:
Aug 24, 2010
Appl. No.:
12/862409
Inventors:
Ann M. Leen - Bellaire TX, US
Ulrike Gerdemann - Houston TX, US
Cliona Rooney - Bellaire TX, US
Juan Vera - Bellaire TX, US
John R. Wilson - New Brighton MN, US
International Classification:
A61K 35/12
C12N 15/85
C40B 50/00
A61P 35/00
A61P 31/12
A61P 37/00
A61P 31/14
A61P 31/16
A61P 31/20
A61P 35/02
US Classification:
424 9371, 435455, 435375
Abstract:
The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.

Engineered Cd19-Specific T Lymphocytes That Coexpress Il-15 And An Inducible Caspase-9 Based Suicide Gene For The Treatment Of B-Cell Malignancies

View page
US Patent:
20130071414, Mar 21, 2013
Filed:
Apr 27, 2012
Appl. No.:
13/458085
Inventors:
Gianpietro Dotti - Houston TX, US
David M. Spencer - Houston TX, US
Cliona M. Rooney - Bellaire TX, US
Malcolm K. Brenner - Bellaire TX, US
International Classification:
A61K 39/00
C12N 5/0783
C12N 15/864
C12N 15/86
C12N 15/861
C12N 15/867
C12N 15/85
C12N 5/07
A61K 38/19
US Classification:
4241841, 4353201, 435455, 424 9371
Abstract:
The present invention generally concerns particular methods and compositions for cancer therapy. In particular embodiments, there methods and compositions related to cells that harbor expression vectors encoding a cytokine and an inducible suicide gene and, optionally, the same or different vector(s) encoding a chimeric antigen receptor and/or a detectable gene product.

Methods Of Cell Culture For Adoptive Cell Therapy

View page
US Patent:
20130102075, Apr 25, 2013
Filed:
May 18, 2012
Appl. No.:
13/475700
Inventors:
Juan F. Vera - Bellaire TX, US
Cliona M. Rooney - Bellaire TX, US
Ann M. Leen - Bellaire TX, US
John R. Wilson - New Brighton MN, US
International Classification:
C12M 1/04
US Classification:
435373, 4352971
Abstract:
An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cmif the growth surface is not comprised of gas permeable material and up to 2 ml/cmif the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×10cells/cmat the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×10cells/cm.

Cytotoxic T Lymphocyte-Mediated Immunotherapy

View page
US Patent:
59623187, Oct 5, 1999
Filed:
Nov 15, 1996
Appl. No.:
8/746726
Inventors:
Cliona Rooney - Memphis TN
Marie Roskrow - Memphis TN
Geoffrey Kitchingman - Millington TN
Colton Smith - Memphis TN
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
A01N 6300
C12N 500
US Classification:
435325
Abstract:
The present invention is directed to methods for stimulating primary and secondary effector cell responses for cellular immunotherapy. Cellular immunotherapy can successfully prevent or treat various viral infections and tumors, such as posttransplant EBV lymphoma. The present invention offers a general method for effecting cellular immunotherapy by providing for presentation, by the most effective antigen presenting cells, viral particles or specific antigens, without the need to develop an active viral infection in the antigen presenting cells. Furthermore, the present invention provides for generating effector cells against more than one opportunistic pathogen, e. g. , Epstein-Barr virus and adenovirus. The effector cells generated according to the invention, which include CD4 and CD8 cells, are extremely long lived in vivo after adoptive transfer. In specific embodiments, dendritic cells present whole adenovirus particles via class I MHC molecules, transduced dendritic cells present a weak EBV antigen to effector cells, and EBV-transformed lymphoblastoid cells present whole adenoviral particles to effector cells, generating a population of effector cells active against EBV and adenovirus.

Generation Of Ctl Lines With Specificity Against Multiple Tumor Antigens Or Multiple Viruses

View page
US Patent:
20220282218, Sep 8, 2022
Filed:
May 26, 2022
Appl. No.:
17/804239
Inventors:
- Houston TX, US
- New Brighton MN, US
Cliona M. Rooney - Bellaire TX, US
Juan F. Vera Valdes - Houston TX, US
John R. Wilson - New Brighton MN, US
International Classification:
C12N 5/0783
A61K 39/00
A61K 39/12
A61K 39/155
A61K 39/245
Abstract:
The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane.

Pepmixes To Generate Multiviral Ctls With Broad Specificity

View page
US Patent:
20220251508, Aug 11, 2022
Filed:
Apr 18, 2022
Appl. No.:
17/659624
Inventors:
- Houston TX, US
Juan Fernando Vera Valdes - Houston TX, US
Cliona M. Rooney - Houston TX, US
Ulrike Gerdemann - Cambridge MA, US
International Classification:
C12N 5/0783
A61K 39/12
C12N 7/00
Abstract:
The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.
Control profile
Cliona Mary Rooney from Bellaire, TX, age ~68 Get Report